XML 54 R24.htm IDEA: XBRL DOCUMENT
v3.19.3

Description of Operations and Summary of Significant Accounting Policies - Description of Operations and Variable Interest Entity (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended |
--- | --- | --- | ---
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018
Description of Operations and Summary of Significant Accounting Policies |  |  |  |  |  |
Cash balance | $ 172,946 |  | $ 172,946 |  | $ 62,417 | [1]
Net revenue | 65,755 | $ 61,680 | 185,045 | $ 181,146 |  |
Total operating expenses | 4,962 | 4,019 | 12,324 | 20,115 |  |
GSK |  |  |  |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |  |  |  |
Net revenue | 65,755 | 61,680 | $ 185,045 | 181,146 |  |
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK |  |  |  |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |  |  |  |
Percentage of economic interest in any future payments made under the agreements |  |  | 15.00% |  |  |
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | RELVAR/BREO |  |  |  |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |  |  |  |
Royalty rate for first level of annual global net sales (as a percent) |  |  | 15.00% |  |  |
Annual global sales level used to determine royalty rate |  |  | $ 3,000,000 |  |  |
Royalty rate for sales above first level of annual global net sales (as a percent) |  |  | 5.00% |  |  |
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Minimum |  |  |  |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |  |  |  |
Royalty rate for combination products (as a percent) |  |  | 6.50% |  |  |
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Maximum |  |  |  |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |  |  |  |
Royalty rate for combination products (as a percent) |  |  | 10.00% |  |  |
TRC |  |  |  |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |  |  |  |
Cash balance | 11,200 |  | $ 11,200 |  |  |
TRC | TRELEGY |  |  |  |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |  |  |  |
Net revenue | 11,200 | $ 3,600 | 28,400 | $ 6,900 |  |
TRC | Collaborative arrangement |  |  |  |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |  |  |  |
Related-party receivables | 11,200 |  | 11,200 |  | $ 6,400 |
Theravance Biopharma | TRC |  |  |  |  |  |
Description of Operations and Summary of Significant Accounting Policies |  |  |  |  |  |
Total operating expenses | $ 2,800 |  | $ 2,900 |  |  |
[1] | Condensed consolidated balance sheet as of December 31, 2018 has been derived from audited consolidated financial statements.

X
- Definition Represents the royalty rate for combination products. + References No definition available. + Details
Name: | inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
Namespace Prefix: | inva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales. + References No definition available. + Details
Name: | inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix: | inva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales. + References No definition available. + Details
Name: | inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix: | inva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement. + References No definition available. + Details
Name: | inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the percentage of economic interest in any future payments made under the agreements. + References No definition available. + Details
Name: | inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements
Namespace Prefix: | inva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Information related to various accounting policies of the entity. + References No definition available. + Details
Name: | inva_SummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix: | inva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_CashAndCashEquivalentsAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.10(3)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.3) -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 + Details
Name: | us-gaap_DueFromRelatedParties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + References No definition available. + Details
Name: | us-gaap_OperatingExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=inva_TheravanceRespiratoryCompanyLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_TrelegyElliptaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=inva_TheravanceBiopharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |